Pronova BioPharma
Pronova BioPharma is a Norwegian pharmaceutical and omega-3 ingredients company known for developing the concentrated omega-3 formulation used in Lovaza and Omacor.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Pronova BioPharma was a Norwegian pharmaceutical company specializing in concentrated omega-3 fatty-acid products and pharmaceutical ingredients. Its roots lay in Norway’s long-established cod-liver-oil industry and in the Bergen company JC Martens, founded in 1838. Pronova was established in 1991 as a spinout from JC Martens and subsequently developed into a specialist supplier of pharmaceutical-grade omega-3 products. The company’s most important contribution was the development of a concentrated omega-3-acid ethyl-esters formulation. This formulation became the active pharmaceutical ingredient for Lovaza in the United States and Omacor in Europe, prescription products used to reduce very high triglyceride levels. Pronova’s role was primarily that of developer and manufacturer of the pharmaceutical ingredient, while commercialization in different markets involved licensing and commercial partners. Pronova obtained European approvals for Omacor in several countries in 2001 after a large clinical program lasting approximately three and a half years and involving about 11,000 subjects. The company later licensed United States and Puerto Rican rights to Reliant Therapeutics in 2004. Reliant and Pronova received United States Food and Drug Administration approval for the product that year, and the medicine was launched in the United States and Europe in 2005. In France, Pronova also worked with Pierre Fabre among other commercial partners. The Lovaza franchise became the company’s central commercial asset. Reported worldwide sales were approximately $144 million in 2005 and $778 million in 2008, although these figures belong to the historical commercial period and are not current Pronova revenue figures. The product’s commercial importance also made the company a target for generic competition. Teva Pharmaceuticals and Par Pharmaceutical pursued abbreviated new drug applications, leading to United States patent litigation. Pronova initially prevailed in district court, but the Federal Circuit later held that a key patent was invalid because an earlier transfer of fish-oil samples for testing constituted public use. Generic versions entered the United States market in April 2014. In addition to finished-product development and licensing, Pronova manufactured omega-3 pharmaceutical ingredients. It also had a Danish bulk-manufacturing operation, including a plant in Kalundborg. The company participated as a commercial partner in MabCent-SFI, a research initiative focused on marine biotechnology and related discovery work. BASF announced an agreement to acquire Pronova in 2012 for approximately $844 million. The transaction was completed after the announcement period, with sources describing the acquisition as taking place in 2013 or 2014. Under BASF ownership, Pronova’s capabilities became part of a larger chemicals and nutrition-and-health organization, while its omega-3 manufacturing heritage continued through the Epax business and related operations. Pronova is therefore best understood today as a historically significant pharmaceutical and marine-lipid business whose principal brand identity is associated with prescription omega-3 development, rather than as an independent publicly traded company.
History
Pronova BioPharma emerged from Norway’s cod-liver-oil and marine-oil tradition. Its historical lineage can be traced to JC Martens, a Bergen company established in 1838. Pronova itself was created in 1991 as a spinout from JC Martens, with a focus on developing more concentrated and standardized omega-3 products for pharmaceutical use. The company’s defining technical achievement was a concentrated formulation of omega-3-acid ethyl esters. This formulation supplied the active pharmaceutical ingredient for prescription products marketed as Omacor in Europe and Lovaza in the United States. Pronova’s business model combined pharmaceutical development, regulatory work, ingredient manufacturing, and partnerships with companies responsible for regional commercialization. In Europe, Pronova secured approvals for Omacor in several countries in 2001. The approval program followed a clinical trial lasting roughly three and a half years and involving approximately 11,000 participants. The company worked with commercial partners including Pierre Fabre in France. In 2004, it licensed United States and Puerto Rican rights to Reliant Therapeutics. Pronova and Reliant obtained FDA approval in the same year, followed by commercial launches in the United States and Europe in 2005. Lovaza became Pronova’s principal commercial success. Historical reports put worldwide sales at approximately $144 million in 2005 and $778 million in 2008. The product’s growth established Pronova as an important specialist in prescription omega-3 therapy and made its manufacturing and intellectual-property capabilities strategically valuable. The company later faced challenges from generic manufacturers. In 2009, Teva Pharmaceuticals and Par Pharmaceutical indicated that they intended to seek approval for generic versions through abbreviated new drug applications. Pronova sued the companies in April 2009, asserting infringement of patents covering Lovaza. A district court sided with Pronova in May 2012, but the Federal Circuit reversed that decision in September 2013. The appellate court concluded that an earlier transfer of fish-oil samples to a researcher for testing amounted to public use occurring more than one year before the relevant patent application, invalidating the patent at issue. Generic Lovaza products reached the United States market in April 2014. Pronova also maintained a manufacturing presence in Denmark. Its Kalundborg facility produced bulk omega-3 products and supported the company’s role as an ingredient supplier. Beyond its commercial operations, Pronova participated in MabCent-SFI as a commercial research partner, linking the company to marine biotechnology and discovery research. BASF announced its intention to acquire Pronova in 2012 in a transaction valued at approximately $844 million. The acquisition was completed after the announcement, with public descriptions variously associating completion with 2013 and 2014. The transaction ended Pronova’s period as an independent listed company and placed its omega-3 expertise within BASF’s broader portfolio. The business and manufacturing heritage subsequently continued under BASF-related operations, including the EPAX omega-3 activities. Pronova’s historical importance rests principally on converting marine-oil expertise into regulated pharmaceutical ingredients and on enabling the Lovaza and Omacor prescription omega-3 franchise.
- 2014
Generic Lovaza products are introduced
[1]Generic versions of Lovaza entered the United States market after the patent litigation outcome.
- 2013
Federal Circuit invalidates key Lovaza patent
[1]The Federal Circuit reversed a district-court ruling and found a key patent invalid because earlier sample testing constituted public use.
- 2012
BASF announces acquisition
[1]BASF announced a proposed acquisition of Pronova valued at approximately $844 million.
- 2009
Generic manufacturers announce Lovaza filings
[1]Teva Pharmaceuticals and Par Pharmaceutical signaled plans to file abbreviated new drug applications for generic versions, triggering patent litigation.
- 2005
Lovaza and Omacor launch in major markets
[1]The prescription omega-3 product was launched in the United States and Europe under the Lovaza and Omacor names.
- 2004
United States rights are licensed to Reliant Therapeutics
[1]Pronova licensed United States and Puerto Rican rights for the product to Reliant Therapeutics, which worked with Pronova on regulatory approval and commercialization.
- 2004
FDA approval for Lovaza
[1]Pronova and Reliant received United States FDA approval for the omega-3 prescription product later marketed as Lovaza.
- 2001
European approvals for Omacor
[1]Pronova obtained approval to market its prescription omega-3 product, called Omacor in Europe, in several European countries after a large clinical program.
- 1991
Pronova is founded as a JC Martens spinout
[1]Pronova BioPharma was formed as a spinout from JC Martens and began developing concentrated omega-3 products for pharmaceutical applications.
- 1838
JC Martens is established in Bergen
[1]The company later associated with Pronova’s corporate heritage, JC Martens, was established in Bergen, Norway, as part of the country’s long cod-liver-oil tradition.
Products and positioning
A specialist pharmaceutical and marine-lipid company positioned around high-purity, concentrated omega-3 ingredients, prescription drug development, and bulk manufacturing for pharmaceutical and health-product partners.
Prescription omega-3 medicine · 2005
Lovaza
Lovaza is the United States brand name for a prescription omega-3 product based on concentrated omega-3-acid ethyl esters. Pronova developed and manufactured the active pharmaceutical ingredient, while United States commercialization was handled through its relationship with Reliant Therapeutics. The product was approved by the FDA in 2004 and launched in the United States in 2005 for the treatment of very high triglyceride levels.
Prescription omega-3 medicine · 2001
Omacor
Omacor is the European brand name for Pronova’s concentrated omega-3 prescription formulation. Pronova received approval to market the product in several European countries in 2001 following an extensive clinical program. The product represented the European counterpart to Lovaza and was commercialized through regional partners, including Pierre Fabre in France.
Bulk pharmaceutical and nutritional ingredients
EPAX omega-3 ingredients
EPAX refers to concentrated omega-3 ingredient activities associated with Pronova’s manufacturing heritage. These products serve as bulk ingredients rather than consumer-facing finished medicines and are manufactured for pharmaceutical, nutrition, and health-product applications. The business continued within BASF-related operations after the acquisition of Pronova.
Brand decisions
2012
Accept acquisition by BASFM&ABackground
Pronova had established a specialized position in pharmaceutical omega-3 ingredients and prescription products, while BASF sought to expand its health and nutrition activities.
Action taken
BASF announced an agreement to acquire Pronova for approximately $844 million.
Aftermath
The transaction ended Pronova’s independence as a publicly traded company and integrated its omega-3 capabilities into BASF’s broader organization.
announced acquisition value. $844 million (2012 announcement)
2009
Sue generic manufacturers over Lovaza patentsOtherBackground
Teva Pharmaceuticals and Par Pharmaceutical announced plans to seek approval for generic Lovaza products.
Action taken
Pronova filed patent-infringement litigation against the companies, asserting rights covering the Lovaza formulation.
Aftermath
Pronova initially won in district court, but the Federal Circuit later reversed the ruling and invalidated a key patent, allowing generic products to enter the United States market in 2014.
- Teva Pharmaceuticals — Pursued an abbreviated new drug application and defended its position in the patent dispute.
- Par Pharmaceutical — Pursued an abbreviated new drug application for a generic version and participated in the patent litigation.
2004
License United States and Puerto Rican rights to Reliant TherapeuticsStrategyBackground
Pronova had developed the omega-3 formulation but used regional commercial partnerships to expand the product into major prescription-drug markets.
Action taken
The company licensed rights in the United States and Puerto Rico to Reliant Therapeutics, which partnered with Pronova on FDA approval and commercialization.
Aftermath
The arrangement led to FDA approval in 2004 and the United States launch of Lovaza in 2005.
Recent events
- 2014
Generic versions of Lovaza enter the United States market[1]
Product generation · Other
Following the Federal Circuit decision concerning the patent estate, generic versions of Lovaza were introduced in the United States.
- 2013
Federal Circuit reverses Lovaza patent ruling[1]
Lawsuit · Other
The United States Court of Appeals for the Federal Circuit reversed the earlier ruling and held that a key patent was invalid because prior transfer of fish-oil samples for testing constituted public use.
- 2012
Pronova announces planned acquisition by BASF[1]
M&A
BASF announced an agreement to acquire Pronova BioPharma for approximately $844 million, seeking to expand its position in omega-3 ingredients and related health and nutrition activities.
- 2012
United States court initially upholds Lovaza patents[1]
Lawsuit
A district court ruled in favor of Pronova in patent litigation involving Teva Pharmaceuticals and Par Pharmaceutical, finding the relevant Lovaza patents valid at that stage of the proceedings.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pronova-biopharma · Editorial policy · How profiles are compiled